SYNAGEVA BIOPHARMA CORP's ticker is GEVA and the CUSIP is 87159A103. A total of 120 filers reported holding SYNAGEVA BIOPHARMA CORP in Q3 2014. The put-call ratio across all filers is 2.08 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2015 | $4,034,000 | +40240.0% | 41,356 | +39665.4% | 0.00% | – |
| Q4 2014 | $10,000 | +42.9% | 104 | 0.0% | 0.00% | – |
| Q3 2014 | $7,000 | -99.2% | 104 | -98.8% | 0.00% | -100.0% |
| Q2 2014 | $927,000 | +140.8% | 8,851 | +90.5% | 0.00% | – |
| Q1 2014 | $385,000 | +654.9% | 4,645 | +491.0% | 0.00% | – |
| Q4 2013 | $51,000 | -96.1% | 786 | -96.2% | 0.00% | -100.0% |
| Q3 2013 | $1,299,000 | -46.2% | 20,512 | -64.3% | 0.00% | -50.0% |
| Q2 2013 | $2,416,000 | – | 57,512 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 9,223,182 | $387,189,000 | 7.66% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 78,486 | $3,295,000 | 0.56% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,485,288 | $104,382,000 | 0.46% |
| HARVEY CAPITAL MANAGEMENT INC | 34,800 | $1,460,000 | 0.45% |
| EMERALD ADVISERS, LLC | 148,232 | $6,223,000 | 0.38% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 148,411 | $6,233,000 | 0.27% |
| ArrowMark Colorado Holdings LLC | 15,500 | $651,000 | 0.18% |
| CR Intrinsic Investors, LLC | 118,161 | $4,963,000 | 0.17% |
| BB BIOTECH AG | 53,549 | $2,248,000 | 0.16% |
| TURNER INVESTMENTS LLC | 209,744 | $8,806,000 | 0.12% |